Videos

A key opinion leader discusses the evolving treatment landscape for radioiodine refractory differentiated thyroid carcinoma, with special consideration of the phase 3 SELECT trial.

Jennifer Marie Suga, MD, discusses how the results from next-generation sequencing tests are assessed to help physicians manage their patients in real-time.

Saeed Sadeghi, MD, comments on the utilization of FGFR2 inhibitors as treatment for advanced cholangiocarcinoma.

Balazs Halmos, MD, MS, discusses the role of EGFR mutations in patients with advanced non—small cell lung cancer.

Lipika Goyal, MD, discusses first-line options for patients with patients with hepatocellular carcinoma.

A primary researcher on the Phase III ADAURA trial provides an overview of the ground-breaking data for managing patients with EGFR-positive NSCLC (non–small cell lung cancer).

Hagen F. Kennecke, MD, MHA, FRCP, medical oncologist, medical director of the Virginia Mason Cancer Institute and current chair of the NCI Rectal-Anal Cancer Task Force, discusses the treatment and screening decision making process for patients with prostate cancer.

Rana R. McKay, MD, discusses the phase 2 OMNIVORE trial of nivolumab and ipilimumab in patients with advanced renal cell carcinoma.

Paul G. Richardson, MD, discusses the response rates observed in the first-in-human phase 1 trial of CC-92480 and dexamethasone in patients with relapsed/refractory multiple myeloma.

Dr Mark Pegram and Dr Julie Gralow discuss treatment options in relapsed/refractory HER2+ metastatic breast cancer.

Caron Jacobson, MD, discusses the safety findings from the phase 2 ZUMA-5 tidal evaluating axicabtagene ciloleucel in patients with follicular lymphoma and marginal zone lymphoma.